LEF administration demonstrated significant immunomodulatory capacity, reducing the serum levels of Th1-associated pro-inflammatory cytokines (IFN-γ, TNF-α, IL-2) while upregulating Th2-derived anti-inflammatory mediators (IL-4, IL-10) in vitiligo mice. The gene discussed is IL4; the disease is vitiligo.